Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
Muhammad Shafiq, Timothy Walmann, Venkat Nutalapati, Cheryl Gibson, Yousaf Zafar
Abstract
BACKGROUND: Many studies have investigated the progression of nonalcoholic fatty liver disease (NAFLD) and its predisposing risk factors, but the conclusions from these studies have been conflicting. More challenging is the fact that no effective treatment is currently available for NAFLD. AIM: To determine the effects of proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors on fatty infiltration of the liver. METHODS: -test (alpha criterion: 0.05). RESULTS: = 0.201). CONCLUSION: PCSK9 inhibitors can slow down or even completely resolve NAFLD.
Topics & Concepts
KexinProprotein convertaseMedicineSubtilisinPCSK9Fatty liverProprotein ConvertasesType 2 diabetesInternal medicinePharmacologyEndocrinologyBiochemistryEnzymeDiabetes mellitusCholesterolLDL receptorDiseaseLipoproteinChemistryLiver Disease Diagnosis and TreatmentCancer, Lipids, and MetabolismLipoproteins and Cardiovascular Health